Exabis Library
Welcome to the e-CCO Library!
P586: A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: the Edinburgh experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P586: Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohn’s disease: a multi-centre retrospective cohort study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P586: Drug-induced lipid changes in patients with Inflammatory Bowel Disease: a single center, prospective study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P586: Surgical recurrence in Crohn’s Disease: Can we prevent it?
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P586: Tofacitinib for the induction and maintenance of medically resistant ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P586: Vedolizumab in Mild to Moderate Crohn's Disease Patients Naïve to Biological Therapy: a Multicentric Observational Study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P587 Adalimumab in pediatric Crohn’s disease: A long-term multi-centre real-world experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P587: Disease severity in the INFLAMMATORY BOWEL DISEASES: Do patients and physicians agree?
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P587: Drug survival of vedolizumab-treated inflammatory bowel disease patients in a nationwide observational cohort study: ICC case series
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P587: Fermentation capacity of gut microbiota in patients with inflammatory bowel disease compared to healthy controls
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P587: Intestinal ultrasound (IUS) and magnetic resonance imaging (MRI) for monitoring of response to therapy in luminal Crohn's disease – a systematic review.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P587: Quality of care indicators in inflammatory bowel disease: local pilot study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P587: Utility of intestinal ultrasound in Inflammatory Bowel Disease patients on management decisions
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P588 vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P588: Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P588: Steroid sparing effect of adalimumab in cortisone–depended ulcerative colitis patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P588: Switching from infliximab originator to a first biosimilar is safe and effective: A single-centre series with through levels and anti-drug antibodies determination
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P588: T cell response to SARS-CoV-2 mRNA vaccines by an interferon-gamma release immunoassay in patients with Inflammatory Bowel disease receiving anti-TNF and thiopurine treatment
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P588: Tacrolimus suppositories: a safe and effective treatment for treatment-refractory proctitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P588: Ustekinumab for the treatment of Crohn's disease patients with TNF antagonist induced psoriasis. Real life experience from a tertiary referral center through week 54
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM